A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis (PASSION Study)

Trial Profile

A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis (PASSION Study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PASSION
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 16 Jun 2018 Results of subgroup analysis evaluating the impact of ADA in clinical, functional, and pt-reported outcome treatment targets and sustained responses by PSP use presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results evaluating the impact of prior bDMARD use on clinical and patient reported outcomes in patients enrolled in the PASSION study. presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results assessing incremental economic value associated with enrollment in the Patient Support Program presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top